May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Glaucoma as a Possible Factor for Vision Loss in the TTT4CNV Clinical Trial
Author Affiliations & Notes
  • E. Reichel
    Ophthal-Tufts Univ Sch of Med, New England Eye Center, Boston, MA, United States
  • D.C. Musch
    Ophthalmology, University of Michigan, Ann Arbor, MI, United States
  • M.W. Johnson
    Ophthalmology, University of Michigan, Ann Arbor, MI, United States
  • D.J. D'Amico
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, United States
  • T.R. Friberg
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA, United States
  • R. Landis
    University of Pennsylvania, Philadelphia, PA, United States
  • M.A. Mainster
    Ophthalmology, University of Kansas, Kansas City, KS, United States
  • Footnotes
    Commercial Relationships  E. Reichel, Iridex C, R; D.C. Musch, None; M.W. Johnson, None; D.J. D'Amico, None; T.R. Friberg, Iridex F; R. Landis, None; M.A. Mainster, Iridex C.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 5043. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Reichel, D.C. Musch, M.W. Johnson, D.J. D'Amico, T.R. Friberg, R. Landis, M.A. Mainster; Glaucoma as a Possible Factor for Vision Loss in the TTT4CNV Clinical Trial . Invest. Ophthalmol. Vis. Sci. 2003;44(13):5043.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: The TTT4CNV Clinical Trial is a study designed to determine if transpupillary thermotherapy (TTT) is effective in preventing further visual loss from occult choroidal neovascularization (CNV) associated with age-related macular degeneration. Methods: A randomized, sham-controlled, multi-centered study. Results: A review of over 280 patients enrolled in the TTT4CNV Clinical Trial revealed that 7 (2.5%) patients were reported to have loss of vision immediately after TTT. Of these 7 patients, 3 (42.9%) had pre-existing glaucoma, whereas the frequency of pre-existing glaucoma among patients receiving TTT who did not experience visual loss was 4.8% (7/147). This significant association [odds ratio, 15.0 (95% CI,2.8,80.4);P=0.006, Fisher's exact test],albeit based on a small number of patients, led the study's Data and Safety Monitoring Committee to advise adding pre-existing glaucoma as an exclusion criterion for further enrollment. Conclusions: Possible reasons why glaucoma could contribute to a higher risk of acute, severe vision loss upon being treated with TTT and considerations for the management of these patients will be discussed.

Keywords: age-related macular degeneration • laser • clinical (human) or epidemiologic studies: tre 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.